Oxycodone News and Research

RSS

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

In response to the growing opioid crisis, several states, including Massachusetts and Rhode Island, have granted pharmacists the authority to provide naloxone rescue kits without a prescription to at-risk patients. This model of pharmacy-based naloxone (PBN) education and distribution is one of the public health strategies currently being evaluated at hundreds of pharmacies in both states to determine the impact on opioid overdose death rates.

25 Aug 2015

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BioDelivery Sciences International, Inc. announced the approval by the U.S. Food and Drug Administration of a Supplemental New Drug Application (sNDA) for a new formulation of ONSOLIS (fentanyl buccal soluble film) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant.

13 Aug 2015

Egalet declares pricing of underwritten public offering of common stock

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $11.25 per share.

28 Jul 2015

Research findings may help health care providers curb painkiller misuse

People who misuse prescription pain relievers all have one thing in common, University of Georgia researchers have discovered: a history of recent illicit drug use. How they acquire such drugs varies according to age, however.

12 Jul 2015

1 in 4 people with histories of nicotine use, substance abuse likely to use opioid painkillers long-term

Opioid painkiller addiction and accidental overdoses have become far too common across the United States. To try to identify who is most at risk, Mayo Clinic researchers studied how many patients prescribed an opioid painkiller for the first time progressed to long-term prescriptions. The answer: 1 in 4. People with histories of tobacco use and substance abuse were likeliest to use opioid painkillers long-term.

2 Jul 2015

Egalet reports top-line results from Category 3 HAL study of Egalet-002

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

30 Jun 2015

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet Corporation today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

29 Jun 2015

Adding tamper resistant properties to medications can help curb prescription drug abuse

Health Canada today published a Notice of Pre-Consultation in Canada Gazette, Part I, seeking stakeholder feedback on draft Tamper-Resistant Properties of Drugs Regulations.

27 Jun 2015

Opioid offers pain relief for Parkinson’s patients

Prolonged-release combined oxycodone/naloxone may provide relief for patients with severe pain related to Parkinson’s disease, a double-blind randomised trial shows.

22 Jun 2015

Wockhardt obtains final approval from FDA for marketing 5mg/ 5ml of Oxycodone HCl liquid

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 5mg/ 5ml of Oxycodone HCl liquid which is used in treatment of moderate to severe acute and chronic pain. Wockhardt is launching the product soon and will be amongst the few generic versions of this product in the market.

22 Jun 2015

Veterans who died from drug overdoses also prescribed benzodiazepines for pain

In a recent study, nearly half of all veterans who died from drug overdoses while prescribed opioids for pain were also receiving benzodiazepines, or benzos, which are common medications for the treatment of anxiety, insomnia and alcohol withdrawal. Veterans prescribed higher doses of benzodiazepines while concurrently receiving opioids were at greater risk of overdose death than those on lower doses of benzodiazepines.

15 Jun 2015

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction.

8 Jun 2015

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

4 Jun 2015

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

1 Jun 2015

Scripps Florida scientists win $2.4 million to expand development of new pain therapies

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.4 million from the National Institute on Drug Abuse of The National Institutes of Health to expand development of new pain medications with fewer side effects than those currently available...

8 May 2015

Egalet announces business highlights, financial results for first quarter 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today reported business highlights and financial results for the three months ended March 31, 2015.

7 May 2015

Oxycodone-related deaths drop 25% after implementation of Prescription Drug Monitoring Program

Oxycodone-related deaths dropped 25 percent after Florida implemented its Prescription Drug Monitoring Program in late 2011 as part of its response to the state's prescription drug abuse epidemic, according to a team of UF Health researchers. The drop in fatalities could stem from the number of health care providers who used the program's database to monitor controlled substance prescriptions.

16 Apr 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015